Synthetic super-enhancers enable precision viral immunotherapy

Area of Science:

• Biotechnology
• Gene Therapy
• Cancer Research

Background:

• Cell-type-specific promoters are crucial for targeted gene therapy but often lack optimal strength and selectivity.
• Glioblastoma stem cells (GSCs) possess unique transcriptional regulatory networks driving tumor growth.

Purpose of the Study:

• To engineer synthetic super-enhancers (SSEs) for robust and selective gene expression in GSCs.
• To evaluate the therapeutic efficacy of SSE-driven gene therapy in a glioblastoma mouse model.

Main Methods:

• Assembling validated enhancer fragments into SSEs targeting SOX2/SOX9 networks in GSCs.
• Utilizing adeno-associated virus vectors for payload delivery (cytotoxic and immunomodulatory).
• Assessing SSE activity and selectivity using single-cell profiling, biochemical assays, and genome-binding data.

Main Results:

• Engineered SSEs demonstrated high activity and selectivity for GSCs.
• Combined cytotoxic and immunomodulatory payload delivery via SSEs achieved curative outcomes in a glioblastoma mouse model.
• IL-12 payload induced immunological memory, preventing tumor recurrence.

Conclusions:

• SSEs effectively harness GSC-specific transcriptional programs for precision gene expression.
• SSE-driven gene therapy offers a promising strategy for aggressive glioblastoma treatment.
• This approach has potential applications in other diseases requiring cell-state-specific gene regulation.